



## Mauna Kea Technologies announces entrance into exclusive negotiations for a licensing agreement for Cellvizio® in an important therapeutic area with a major industry player

*The Company also confirms that it is pursuing licensing discussions in other therapeutic areas*

*The protective framework of the safeguard proceedings enables Mauna Kea Technologies to intensify discussions on financing options with long-term investors*

Paris and Boston, April 01, 2025 – 8:50 a.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces entering into exclusive negotiations for a licensing agreement for its Cellvizio technology in an important therapeutic area with a major industry player.

As part of its strategic process launched a few months ago, the Company is also pursuing several licensing discussions covering other therapeutic areas, reflecting a growing interest in the Cellvizio technology across multiple medical specialties.

In parallel, and following the opening of the safeguard procedure announced on March 31, 2025, the Company intends to intensify its discussions regarding financing options with long-term investors in order to consolidate its financial position and support its future growth.

*“This exclusive negotiation agreement is a concrete example of the implementation of our strategy to monetize technological assets, and demonstrates the growing attractiveness of our Cellvizio platform to major players in the industry,”* said **Sacha Loiseau, Chairman and CEO of Mauna Kea Technologies**. *“The safeguard proceedings now provide us with a structured framework to accelerate this strategy and enter into long-term discussions with industry and financial partners.”*

\*\*\*

### **About Mauna Kea Technologies**

Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit [www.maunakeatech.com](http://www.maunakeatech.com).

### **Mauna Kea Technologies**

[investors@maunakeatech.com](mailto:investors@maunakeatech.com)

### **NewCap - Investor Relations**

Aurélie Manavarere / Thomas Grojean  
+33 (0)1 44 71 94 94  
[maunakea@newcap.eu](mailto:maunakea@newcap.eu)



## Disclaimer

This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Technologies' financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are subject to numerous risks and uncertainties, including those described in Chapter 2 of Mauna Kea Technologies' 2023 Annual Report filed with the *Autorité des marchés financiers* (AMF) on April 30, 2024, which is available on the Company's website ([www.maunakeatech.fr](http://www.maunakeatech.fr)), as well as the risks associated with changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document.